Factors associated with discontinuation of aripiprazole treatment after switching from other antipsychotics in patients with chronic schizophrenia: A prospective observational study

Psychiatry Research

Volumn 236, Issue , 2016, Pages 71-74

  Takaesu, Yoshikazu ^a   Kishimoto, Taishiro ^c   Murakoshi, Akiko ^a   Takahashi, Nobutada ^b   Inoue, Yuichi ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b Fuji Psychosomatic Rehabilitation Laboratory   (Japan)

^c KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Aripiprazole; Discontinuation; Partial agonist; Predictor; Super sensitivity; Switching; Worsening

Indexed keywords

ARIPIPRAZOLE; BLONANSERIN; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; AGGRESSION; AKATHISIA; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; DELUSION; DEMOGRAPHY; DISEASE DURATION; DISEASE EXACERBATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FOLLOW UP; HALLUCINATION; HUMAN; HYPERPROLACTINEMIA; MALE; MULTIPLE REGRESSION; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NAUSEA; OBSERVATIONAL STUDY; OPEN STUDY; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SCHIZOPHRENIA; SEDATION; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; TREATMENT DURATION; WEIGHT GAIN; MIDDLE AGED; TIME FACTOR; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; YOUNG ADULT;

ADULT; ANTIPSYCHOTIC AGENTS; ARIPIPRAZOLE; DRUG SUBSTITUTION; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SCHIZOPHRENIA; TIME FACTORS; TREATMENT OUTCOME; WITHHOLDING TREATMENT; YOUNG ADULT;

EID: 84957431443     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2015.12.030     Document Type: Article

References (17)

1. Fleischhacker W.W., Heikkinen M.E., Olie J.P., Landsberg W., Dewaele P., McQuade R.D., Loze J.Y., Hennicken D., Kerselaers W. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int. J. Neuropsychopharmacol. 2010, 13:1115-1125.
2. Goodnick P.J., Jerry J.M. Aripiprazole: profile on efficacy and safety. Expert Opin. Pharmacother. 2002, 3:1773-1781.
3. Hsieh M.H., Lin W.W., Chen S.T., Chen K.C., Chen K.P., Chiu N.Y., Huang C., Chang C.J., Lin C.H., Lai T.J. A 64-week, multicenter, open-label study of aripiprazole effectiveness in the management of patients with schizophrenia or schizoaffective disorder in a general psychiatric outpatient setting. Ann. Gen. Psychiatry 2010, 9:35.
4. Inada T., Yagi G. Current topics in neuroleptic-induced extrapyramidal symptoms in Japan. Keio J. Med. 1996, 45:95-99.
5. Kern R.S., Green M.F., Cornblatt B.A., Owen J.R., McQuade R.D., Carson W.H., Ali M., Marcus R. The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine. Psychopharmacology 2006, 187:312-320.
6. Kim S.W., Shin I.S., Kim J.M., Lee J.H., Lee Y.H., Yang S.J., Yoon J.S. Effectiveness of switching to aripiprazole from atypical antipsychotics in patients with schizophrenia. Clin. Neuropharmacol. 2009, 32:243-249.
7. Lin H.C., Chong M.Y., Lee Y., Yeh W.C., Lin P.Y. Switching of antipsychotics to aripiprazole in the treatment of schizophrenia. Chang Gung Med. J. 2009, 32:409-416.
8. Marder S.R., McQuade R.D., Stock E., Kaplita S., Marcus R., Safferman A.Z., Saha A., Ali M., Iwamoto T. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr. Res. 2003, 61:123-136.
9. Newcomer J.W., Campos J.A., Marcus R.N., Breder C., Berman R.M., Kerselaers W., L'Italien G.J., Nys M., Carson W.H., McQuade R.D. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. J. Clin. Psychiatry 2008, 69:1046-1056.
10. Shapiro D.E. The interpretation of diagnostic tests. Stat. Methods Med. Res. 1999, 8:113-134.
11. Stroup T.S., McEvoy J.P., Ring K.D., Hamer R.H., LaVange L.M., Swartz M.S., Rosenheck R.A., Perkins D.O., Nussbaum A.M., Lieberman J.A. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am. J. Psychiatry 2011, 168:947-956.
12. Swets J.A. Measuring the accuracy of diagnostic systems. Science 1988, 240:1285-1293.
13. Takeuchi H., Remington G. A systematic review of reported cases involving psychotic symptoms worsened by aripiprazole in schizophrenia or schizoaffective disorder. Psychopharmacology 2013, 228:175-185.
14. Takeuchi H., Uchida H., Suzuki T., Watanabe K., Kashima H. Predictors of clinical worsening after a switch to aripiprazole in patients with schizophrenia: a 1-year naturalistic follow-up study. J. Clin. Psychopharmacol. 2009, 29:394-395.
15. Takeuchi H., Uchida H., Suzuki T., Watanabe K., Kashima H. Changes in metabolic parameters following a switch to aripiprazole in Japanese patients with schizophrenia: One-year follow-up study. Psychiatry Clin. Neurosci. 2010, 64:104-106.
16. Watanabe M., Matsumura H. Reliability and validity of Subjective Well-being under Neuroleptic drug treatment Short form Japanese version (SWNS-J). Jpn. J. Clin. Psychopharmacol. 2003, 6:905-912.
17. Weiden P.J., Preskorn S.H., Fahnestock P.A., Carpenter D., Ross R., Docherty J.P. Translating the psychopharmacology of antipsychotics to individualized treatment for severe mental illness: a roadmap. J. Clin. Psychiatry 2007, 68(7):S1-S48.